Nov 132017

Representatives of Corporacion Innovarte, Patient Foundation Nuevo Renacer, Pharmaceutical Chemists Guild, and cancer and hepatitis patients attended the Presidential Palace “La Moneda” on November 10th to deliver a letter to the Chilean President of the Republic, Michelle Bachelet, asking her to instruct the Ministry of Health to declare that there are public health reasons justifying the issuance of non voluntary licenses for the patents that prevent entry into Chile of the latest generics for the treatment of Hepatitis C and Prostate Cancer.

They were supported by a number of congressmen, such as  Giorgio Jackson, Miguel Ángel Alvarado and Gabriel Boric. Continue reading »


Compulsory License for Anti-Cancer Drugs – Update from Campaign for Affordable Trastuzumab

 Posted by on January 14, 2013  Comments Off on Compulsory License for Anti-Cancer Drugs – Update from Campaign for Affordable Trastuzumab
Jan 142013

india-flagPress Release by the Campaign for Affordable Trastuzumab


Kalyani Menon-Sen: +91 9910306382, kmenonsen[at]
Leena Menghaney:  +91 9811365412, leenamenghaney [at]

The Campaign for Affordable Trastuzumab welcomes the news that the Government of India has started the process of issuing compulsory licences for the manufacture of biosimilars of three cancer drugs – Trastuzumab, Dasatinib and Ixabepilone. [See Govt moves to make three key cancer drugs cheaper, 12 Jan 13, New Delhi, Indian Express] Continue reading »

Jun 282012

USPTO Deputy Director Teresa Stanek Rea

In testimony before the U.S. House of Representatives Subcommittee on Intellectual Property, Competition and the Internet on 27 June 2012 (Hearing: Protecting Patents, Trade Secrets, and Market Access), the Deputy Director of the U.S. Patent and Trademark Office, who also serves as Undersecretary of Commerce for Intellectual Property, grossly misrepresented the scope of permissible compulsory licensing under the WTO TRIPS Agreement.

In her misleading testimony, Teresa Stanek Rea said:  “We are consistent on our efforts … of trying to stop these compulsory licenses.” Rea said she was particularly disappointed in March, when India’s Patents Office ordered Bayer AG to grant an Indian generics maker (Natco) a compulsory license for the cancer drug Nexavar, ruling that it was too expensive for most people to afford.  (Note:  the generic was 3% the cost of overpriced Bayer product and reached only a tiny fraction of eligible cancer patients in India.)   Continue reading »


GTPI supports judicial decision annulling patent HIV / AIDS medicine

 Posted by on March 26, 2012  Comments Off on GTPI supports judicial decision annulling patent HIV / AIDS medicine
Mar 262012

Below is the  Statement of the Grupo de Trabalho Sobre, Propriedade Intelectual on the Brazlian government’s decision to annul Abbott Laboratories’ patent on lopinavir+ritonavir, an important antiretroviral medicine for the treatment of HIV/AIDS.  The statement was originally released on the 14th of March.

Through an article published by the newspaper Folha de São Paulo on March 9, 2012, the decision issued by Judge Daniela Pereira Madeira from the Federal Court of Rio de Janeiro became widely known. On February 23rd, the Judge granted the request made by the company Cristália, a Brazilian laboratory that produces generics, which demanded the annulment of patent PP1100397-99, held by Abbott Laboratories. Granted through the pipeline mechanism, the patent prevents the local production or importation of generic versions of the drug ritonavir and lopinavir (lop/r) (brand name Kaletra®), used to treat HIV infection. Thus, the Brazilian government can only buy the medicine from Abbott, despite the existence of generic versions sold in the international market at much lower prices. The price paid by Brazil is US$763 per patient/year, but there are generic versions of approved quality by the World Health Organization (WHO) sold for US$402 per patient/year, a price 47% lower. Continue reading »

Mar 122012

India has granted Natco Pharma Ltd. a compulsory license to produce generic sorafenib tosylate – a drug used to treat kidney and liver cancer that is patented by Bayer and sold under the brand name Nexaver. Under the terms of the license, Natco will sell the generic drug for a price not to exceed Rs. 8880 (USD 178) for a one month supply, and will pay a 6% royalty to Bayer. Continue reading »

Jan 232012

The Indian pharmaceutical company Natco has applied for a compulsory license for sorafenib, an anticancer drug sold by Bayer under the brand name Nexavar. The price charged by Bayer is Rs 2,80,428 per month (USD 5,600), a price unaffordable to the majority of Indians in need of the drug (the compulsory license application shows that very few people in need of the medicine receive it).  Cipla produced a generic version of the drug which it sold for a tenth of Bayer’s price, but it now faces an infringement action.   Natco intends to sell the drug for even less if it receives the compulsory license. Continue reading »


UN High Level Meeting Debates TRIPS Flexibilities for Non Communicable Diseases

 Posted by on September 23, 2011  Comments Off on UN High Level Meeting Debates TRIPS Flexibilities for Non Communicable Diseases
Sep 232011

On September 19-20, the UN held a High Level Meeting to develop a global strategy to fight Non-Communicable Diseases (NCDs), “principally cardiovascular diseases, cancers, chronic respiratory diseases and diabetes.” A draft resolution was developed prior to the meeting for ratification and delivery to the UN General Assembly. The U.S. lobbied for the removal of references to the 2001 Doha Declaration on TRIPS and Public Health from the draft declaration – reference to the Doha Declaration would have reinforced that the TRIPS Agreement flexibilities regarding compulsory licenses are available to all, not only countries facing specific emergencies. Continue reading »